Miguel Ángel Labrador-Espinosa

Miguel Ángel Labrador-Espinosa

Auto-generated profile, based on publicly available information

Miguel Ángel Labrador-Espinosa

Unidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, 41013, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2023 in Movement Disorders
Verified
Journal Article
Open access
LMLaura Muñoz‐Delgado
Laura Muñoz‐Delgado
MLMiguel Ángel Labrador‐Espinosa
Miguel Ángel Labrador‐Espinosa
DMDaniel Macías‐García
Daniel Macías‐García
SJSilvia Jesús
Silvia Jesús
BZBelén Benítez Zamora
Belén Benítez Zamora
PMPablo Mir
Pablo Mir
Background: Peripheral inflammatory immune responses are suggested to play a major role in dopaminergic degeneration in Parkinson's disease (PD). The neutrophil‐to‐lymphocyte ratio (NLR) is a well‐established biomarker of systemic inflammation in PD. Degeneration of the nigrostriatal dopaminergic system can be assessed in vivo using [123I]FP‐CIT single photon emission computed tomography imaging of striatal dopamine transporter (DAT) density.Objectives: To assess the relationship between the peripheral immune profile (NLR, lymphocytes, and neutrophils) and striatal DAT density in patients with PD.Methods: We assessed clinical features, the peripheral immune profile, and striatal [123I]FP‐CIT DAT binding levels of 211 patients with PD (primary‐cohort). Covariate‐controlled associations between the immune response and striatal DAT levels were assessed using linear regression analyses. For replication purposes, we also studied a separate cohort of 344 de novo patients with PD enrolled in the Parkinson's Progression Markers Initiative (PPMI‐cohort).Results: A higher NLR was significantly associated with lower DAT levels in the caudate (primary‐cohort: β = −0.01, p < 0.001; PPMI‐cohort: β = −0.05, p = 0.05) and the putamen (primary‐cohort: β = −0.05, p = 0.02; PPMI‐cohort: β = −0.06, p = 0.02). Intriguingly, a lower lymphocyte count was significantly associated with lower DAT levels in both the caudate (primary‐cohort: β = +0.09, p < 0.05; PPMI‐cohort: β = +0.11, p = 0.02) and the putamen (primary‐cohort: β = +0.09, p < 0.05, PPMI‐cohort: β = +0.14, p = 0.01), but an association with the neutrophil count was not consistently observed (caudate; primary‐cohort: β = −0.05, p = 0.02; PPMI‐cohort: β = 0, p = 0.94; putamen; primary‐cohort: β = −0.04, p = 0.08; PPMI‐cohort: β = −0.01, p = 0.73).Conclusions: Our findings across two independent cohorts suggest a relationship between systemic inflammation and dopaminergic degeneration in patients with PD. This relationship was mainly driven by the lymphocyte count. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

26 July 2023 in Movement Disorders
Verified
Journal Article
Open access
MLMiguel A. Labrador‐Espinosa
Miguel A. Labrador‐Espinosa
Jesús Silva-RodríguezJesús Silva-Rodríguez
Jesús Silva-Rodríguez
MRMaría Isabel Reina‐Castillo
María Isabel Reina‐Castillo
PMPablo Mir
Pablo Mir
MGMichel J. Grothe
Michel J. Grothe
Background: Degeneration of the cortically‐projecting cholinergic basal forebrain (cBF) is a well‐established pathologic correlate of cognitive decline in Parkinson's disease (PD). In Alzheimer's disease (AD) the effect of cBF degeneration on cognitive decline was found to be mediated by parallel atrophy of denervated cortical areas.Objectives: To examine whether the association between cBF degeneration and cognitive decline in PD is mediated by parallel atrophy of cortical areas and whether these associations depend on the presence of comorbid AD pathology.Methods: We studied 162 de novo PD patients who underwent serial 3 T magnetic resonance imaging scanning (follow‐up: 2.33 ± 1.46 years) within the Parkinson's Progression Markers Initiative. cBF volume and regional cortical thickness were automatically calculated using established procedures. Individual slopes of structural brain changes and cognitive decline were estimated using linear‐mixed models. Associations between longitudinal cBF degeneration, regional cortical thinning, and cognitive decline were assessed using regression analyses and mediation effects were assessed using nonparametric bootstrap. Complementary analyses assessed the effect of amyloid‐β biomarker positivity on these associations.Results: After controlling for global brain atrophy, longitudinal cBF degeneration was highly correlated with faster cortical thinning (PFDR < 0.05), and thinning in cBF‐associated cortical areas mediated the association between cBF degeneration and cognitive decline (rcBF‐MoCA = 0.30, P < 0.001). Interestingly, both longitudinal cBF degeneration and its association with cortical thinning were largely independent of amyloid‐β status.Conclusions: cBF degeneration in PD is linked to parallel thinning of cortical target areas, which mediate the effect on cognitive decline. These associations are independent of amyloid‐β status, indicating that they reflect proper features of PD pathophysiology. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

5 December 2024 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
MLMiguel A. Labrador-Espinosa
Miguel A. Labrador-Espinosa
JSJesús Silva-Rodriguez
Jesús Silva-Rodriguez
NONiels Okkels
Niels Okkels
LMLaura Muñoz-Delgado
Laura Muñoz-Delgado
JHJacob Horsager
Jacob Horsager
MGMichel J. Grothe
Michel J. Grothe

3 July 2026 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PFPaula Fernández-Rodríguez
Paula Fernández-Rodríguez
PFPablo Franco-Rosado
Pablo Franco-Rosado
PDPatricia Diaz-Galvan
Patricia Diaz-Galvan
LMLaura Muñoz-Delgado
Laura Muñoz-Delgado
ALAntonio Cristobal Luque-Ambrosiani
Antonio Cristobal Luque-Ambrosiani
PMPablo Mir
Pablo Mir
Purpose: To evaluate whether semiquantitative striatal [¹²³I]FP-CIT SPECT-derived metrics improve clinical differentiation of degenerative parkinsonism using an integrated machine learning approach. Methods: This cross-sectional study included 487 patients with Parkinson’s disease (PD) and 219 with atypical parkinsonisms (APS), classified as progressive supranuclear palsy (PSP, n = 127), multiple system atrophy parkinsonian type (MSA-P, n = 37), multiple system atrophy cerebellar type (MSA-C, n = 12), and corticobasal degeneration (CBD, n = 43). All participants underwent a [¹²³I]FP-CIT SPECT. Striatal [¹²³I]FP-CIT uptake was quantified using anatomical (caudate, putamen, ventral striatum) and functional (limbic, executive, sensorimotor) parcellations to calculate specific binding ratios, asymmetry indices, and inter-regional ratios. Discriminative performance of each metric was evaluated using receiver operating characteristic (ROC) curves analyses. A random forest classifier integrating all semiquantitative metrics was trained and validated, enabling data-driven identification diagnostic pathways. Results: Caudate-to-putamen and sensorimotor-to-limbic inter-regional ratios showed the strongest discriminative performance (AUC up to 0.95) for differentiating PD from APS. The random forest achieved a 64% overall accuracy with high per-class specificities (> 84%) and revealed two diagnostic pathways. A lower caudate-to-posterior putamen ratio, primarily grouped PSP, CBD and MSA-C, where lower contralateral sensorimotor uptake pointing to PSP while higher values and ipsilateral caudate uptake subregion further distinguishing CBD from MSA-C. A higher caudate-to-posterior putamen ratio, included PD and MSA-P, where lower ipsilateral caudate uptake together with a higher sensorimotor-to-cognitive ratio mainly differentiate both groups. Conclusions: Integrating anatomical and functional [¹²³I]FP-CIT SPECT metrics within a machine learning framework enhances the clinical differentiation of degenerative parkinsonisms and supports [¹²³I]FP-CIT SPECT as a robust in vivo disease biomarker.